상세 보기
자료 필터
자료유형
발행연도
1996 ~ 2043
1996 2043
키워드
언어
전체 482건 중 21번부터 30번까지의 결과를 표시합니다.
2026
Article
Cannabidiol enhances tamoxifen efficacy via CREB-mediated suppression of ERα signaling in ER-positive breast cancer cells
- Kim, Bu Gyeom ;
- Kim, Okhyeon ;
- Lee, Do-Yeon ;
- Kim, Bo Ram ;
- Kim, Dae Yeong ;
- ... Namgung, Yoon ;
- ... Bong, Jun Woo ;
- ... Kang, Sang hee ;
- ... Lee, Sun Il ;
- ... Oh, Sang Cheul
- 2026-12
- Cell and Bioscience
- Society of Chinese Bioscientists in America
Article
EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer
- Nakayama, Izuma ;
- Ryu, Min-Hee ;
- Lim, Sung Hee ;
- Kim, Jong Gwang ;
- Omori, Takeshi ;
- ... Oh, Sang Cheul ;
- 외 16명
- 2026-08
- Journal of Clinical Oncology
- American Society of Clinical Oncology
Conference
Biomarker and pharmacokinetics (PK) analyses of zolbetuximab from the phase 2 GLEAM study in patients (pts) with claudin 18 isoform 2 (CLDN18.2)+ metastatic pancreatic adenocarcinoma (mPAC)
- Park, W. ;
- Shen, L. ;
- Ducreux, M. P. ;
- Mitsunaga, S. ;
- Roth, G. ;
- ... Oh, Sang Cheul ;
- 외 13명
- 2026-07-03
- 독일
Conference
Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in patients (pts) with claudin 18 isoform 2 (CLDN18.2)+ metastatic pancreatic adenocarcinoma (mPAC): phase II GLEAM study
- Park, W. ;
- Shen, L. ;
- Ducreux, M. P. ;
- Mitsunaga, S. ;
- Roth, G. ;
- ... Oh, Sang Cheul ;
- 외 14명
- 2026-07-02
- 독일
Article
Nivolumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4)
- Kang, Yoon-Koo ;
- Ryu, Min-Hee ;
- Oh, Do-Youn ;
- Oh, Sang Cheul ;
- Rha, Sun Young ;
- 외 14명
- 2026-07
- Cancer Research and Treatment
- 대한암학회
Conference
ONO-4578 combined with nivolumab (NIVO) and chemotherapy (chemo) as first-line (1L) treatment for patients with HER2-negative unresectable advanced or recurrent (adv/rec) gastric/gastroesophageal junction cancer (G/GEJ): A randomized, double-blind, phase 2 trial (ONO-4578-08).
- Lim, Sung Hee ;
- Nakayama, Izuma ;
- Ryu, Min-Hee ;
- Kim, Jong Gwang ;
- Omori, Takeshi ;
- ... Oh, Sang Cheul ;
- 외 13명
- 2026-06-01
- 미국
Conference
Nivolumab plus ipilimumab combined with chemotherapy as first-line treatment for HER2-negative unresectable advanced or recurrent gastric/gastroesophageal junction cancer: A randomized phase 3 trial (ATTRACTION-6).
- Oh, Do-Youn ;
- Kang, Yoon-Koo ;
- Shitara, Kohei ;
- Chen, Li-Tzong ;
- Boku, Narikazu ;
- ... Oh, Sang Cheul ;
- 외 14명
- 2026-06-01
- 미국